* Cypros Pharmaceutical Corp., of Carlsbad, Calif.,broadened its Phase II program for CPC-211 by starting atrial in closed head injury patients. The molecule alreadyis in a Phase II study in stroke.
* Osteotech Inc., of Shrewsbury, N.J., said the FDAdesignated Grafton Demineralized Bone Matrix as withinthe current scope of Banked Human Tissue under theinterim rule on Human Tissue Intended forTransplantation. A designation as a combination product,based on the product's glycerol content, would haverequired Osteotech to conduct clinical studies.
* Protein Polymer Technologies Inc., of San Diego, saidholders of its Series C preferred stock provided thecompany with a $500,000 bridge loan.
(c) 1997 American Health Consultants. All rights reserved.